Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1732

Sort by

Sort Order Select

Journal Articles

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Blood (2019) 134 (23): 2036–2045.

https://doi.org/10.1182/blood.2019000069

Published: 2019

Includes: Supplemental data

Journal Articles

Thrombin Generation in Nephrotic Syndrome Is Dependent on Remission Status and Hypercholestrolemia

Bryce Kerlin, Amanda P. Waller, PhD, Jonathan P. Troost, PhD, Samir Parikh, MD, William E. Smoyer, MD, Matthias Kretzler, MD

Blood (2019) 134 (Supplement_1): 2422.

https://doi.org/10.1182/blood-2019-128680

Published: 2019

Journal Articles

Protein Cysteine Sulfenylation By CD36-Dependent Reactive Oxygen Species Signaling Promotes Platelet Activation

Moua Yang, PhD, Calvin Harberg, Wenjing Chen, Sarah L. Wynia-Smith, PhD, Kate S. Carroll, PhD, Jacek Zielonka, PhD, Roy L. Silverstein, MD, Brian C. Smith, PhD

Blood (2019) 134 (Supplement_1): 2338.

https://doi.org/10.1182/blood-2019-122465

Published: 2019

Journal Articles

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Charles Macaulay, MSc, BA, Stefan Alig, MD, David M. Kurtz, MD PhD, Michael C. Jin, BS, Stephen Opat, Joanne Soo, MD, Brian Sworder, MD PhD, Mark S. Hertzberg, MD PhD, Maher K. Gandhi, PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 1600.

https://doi.org/10.1182/blood-2019-131278

Published: 2019

Journal Articles

A Combination of CD302 gene Expression and 3-Months BCR-ABL1 Level Predicts Inferior Achievement of Deep Molecular Response in CP-CML Patients Treated with Imatinib

Chung Hoow Kok, PhD BSc, Liu Liu, PhD BSc, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Verity A Saunders, Phuong Dang, Timothy P. Hughes, MDMBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 663.

https://doi.org/10.1182/blood-2019-125446

Published: 2019

Journal Articles

Prospective Evaluation of ABL Kinase Domain Mutational Analysis By Next-Generation-Sequencing in Newly Diagnosed CP CML Patients Undergoing First-Line Treatment with Nilotinib Alone or Nilotinib + Pegylated Interferon-α2a in a Prospective Phase III Trial

Hugues de Lavallade, MD PhD, Sophie Jackson, BSc, Aytug Kizilors, PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnes Guerci-Bresler, MD PhD, Delphine Rea, MD, Claudine Chollet, MSc, Stephane Morisset, BioStat, Fanny Robbesyn, BSc, Francois-Xavier Mahon, MD PhD, Stephanie Dulucq, PharmD, PhD, Franck E Nicolini, MD PhD

Blood (2019) 134 (Supplement_1): 664.

https://doi.org/10.1182/blood-2019-125108

Published: 2019

Journal Articles

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Kathryn E Flynn, PhD, Kevin P. Weinfurt, PhD, Li Lin, MS, Jerald P. Radich, MD, Charles A. Schiffer, MD, Michael J. Mauro, MD, Javier Pinilla Ibarz, MD PhD, Joseph O. Moore, MD, Richard A. Larson, MD, Vivian G. Oehler, MD, Michael W. Deininger, James E. Thompson, MD, Neil P Shah, MD PhD, Martha Wadleigh, MD, Ellen K. Ritchie, MD, Richard T. Silver, MD, Jorge E. Cortes, MD, Vamsi Kota, Ehab L. Atallah, MD

Blood (2019) 134 (Supplement_1): 705.

https://doi.org/10.1182/blood-2019-126002

Published: 2019

Journal Articles

HDAC8 Promotes MLL-Rearranged Acute Myeloid Leukemia By Inhibiting p53 Acetylation

Dijiong Wu, MD, Man Li, PhD, Lianjun Zhang, PhD, Jing Qi, PhD, Chun-Wei David Chen, PhD, Xin He, PhD, Yinghui Zhu, PhD, Haojie Dong, PhD, Jie Sun, PhD, Ling Li, PhD, Guido Marcucci, MD, Ya-Huei Kuo, PhD

Blood (2019) 134 (Supplement_1): 642.

https://doi.org/10.1182/blood-2019-124134

Published: 2019

Journal Articles

Characterization of Recombinant β2GPI Using Hydrogen-Deuterium Exchange and X-Ray Crystallography

Ravi Kumar Alluri, PhD, Nicholas Arce, Philip Klenotic, Chih Chia Su, PhD, Suman Kundu, MBA, Edward Yu, PhD, Renhao Li, PhD, Keith R McCrae, MD

Blood (2019) 134 (Supplement_1): 1105.

https://doi.org/10.1182/blood-2019-131386

Published: 2019

Journal Articles

In Vitro Functionality of hiPSC Derived PLT+: The Utility of Microfluidic Assays in Determining Potency

Marcus Lehmann, PhD, Annie K Burton, Savannah G Szemethy, Jorge Valdez, PhD, Jonathan N. Thon, PhD

Blood (2019) 134 (Supplement_1): 1168.

https://doi.org/10.1182/blood-2019-131896

Published: 2019

Journal Articles

Prothrombotic State, Platelet Activation and Netosis in Systemic Lupus Erythematosus

Elena Monzón Manzano, Ihosvany Fernandez-Bello, Raul Justo Sanz, Larissa Valor, Francisco Javier López-Longo, Angel Robles, Teresa Álvarez Roman, Miguel A Canales, MD PhD, Victor Jimenez-Yuste, Nora Butta, PhD

Blood (2019) 134 (Supplement_1): 1141.

https://doi.org/10.1182/blood-2019-127991

Published: 2019

Journal Articles

Fibrinogen-Mediated Platelet Microaggregate Formation in Stored Whole Blood

Michael Adam Meledeo, PhD, Grantham Peltier, MS, James Bynum, PhD, Andrew P. Cap, MD PhD

Blood (2019) 134 (Supplement_1): 1172.

https://doi.org/10.1182/blood-2019-131053

Published: 2019

Journal Articles

Platelet and Immune Characteristics of Patients with Immune Thrombocytopaenia Non Responders to Therapeutic Treatments

Elena Monzón Manzano, Raul Justo Sanz, Diana Hernández, Teresa Álvarez Roman, Ihosvany Fernandez-Bello, Mónica Martín, Larissa Valor, María Isabel Rivas Pollmar, Miguel A Canales, MD PhD, Victor Jimenez-Yuste, Nora Butta, PhD

Blood (2019) 134 (Supplement_1): 1089.

https://doi.org/10.1182/blood-2019-125772

Published: 2019

Journal Articles

Dominant Role of αIIbβ3 in Platelet Interactions with Polymerizing Cross-Linked Fibrin

Claudia Lorena Buitrago, PhD, Barry S. Coller, MD, Hina Zafar

Blood (2019) 134 (Supplement_1): 1061.

https://doi.org/10.1182/blood-2019-122753

Published: 2019

Journal Articles

RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia

Christina A. Snider, BA, Kevin Fung, Francesca Gould, Vera Adema, PhD, Cassandra M Kerr, MS, Sunisa Kongkiatkamon, Hassan Awada, MD, Milo Co, Teodora Kuzmanovic, BA, Bhumika J. Patel, MD, Aaron T. Gerds, MD MS, Sudipto Mukherjee, MD PhD MPH, Aziz Nazha, MD, Hetty E. Carraway, MD MBA, Tomas Radivoyevitch, PhD, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD, Mikkael A. Sekeres, MD MS, Anjali S. Advani, MD

Blood (2019) 134 (Supplement_1): 2696.

https://doi.org/10.1182/blood-2019-126311

Published: 2019

Journal Articles

Cell Type-Specific Effects of Crizotinib in Human Acute Myeloid Leukemia with TP53 Alterations

Marie Lue Antony, PhD, Klara Noble-Orcutt, Oluwateniayo Ogunsan, Fiona He, MD, Zohar Sachs, MD PhD

Blood (2019) 134 (Supplement_1): 2563.

https://doi.org/10.1182/blood-2019-130487

Published: 2019

Journal Articles

Combination of Dasatinib and Pediatric-Inspired Regimens in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Single-Center Prospective Study

Zhang Guang ji, Sr., master, Jianxiang Wang, MD, Ying Wang, Hui Wei, MD, Yingchang Mi, MD

Blood (2019) 134 (Supplement_1): 2583.

https://doi.org/10.1182/blood-2019-126480

Published: 2019

Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

Blood (2019) 134 (Supplement_1): 2926.

https://doi.org/10.1182/blood-2019-125740

Published: 2019

Journal Articles

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Maria R Vazquez, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Susan O'Brien, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Guillermo Garcia-Manero, MD, Sara E Dellasala, BS, Kathleen A Kehr, MD, Sherry A. Pierce, BSN, BA, Mary B. Rios, RN, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 2927.

https://doi.org/10.1182/blood-2019-132246

Published: 2019

Journal Articles

The Relationship between Molecular Response of BCR-ABL1 Transcripts within 6 Months and Deep Molecular Response at 18 Months to Dasatinib Treatment for Newly Diagnosed Patients with CML-CP

Daigo Michimata, MD, Kazunori Murai, MD PhD, Yasuro Miyairi, MD, PhD, Yoshiaki Okano, MD, PhD, Yuuzou Suzuki, MD, PhD, Hiroyuki Hamada, MD, Akiyoshi Sato, MD, PhD, Tatsuo Oyake, Shugo Kowata, MD, PhD, Yasuhiko Tsukushi, MD, PhD, Norifumi Sugawara, MD, PhD, Akihiro Otsu, MD, PhD, Kenji Shimosegawa, MD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2019) 134 (Supplement_1): 2928.

https://doi.org/10.1182/blood-2019-125066

Published: 2019

NARROW

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Thrombin Generation in Nephrotic Syndrome Is Dependent on Remission Status and Hypercholestrolemia

Protein Cysteine Sulfenylation By CD36-Dependent Reactive Oxygen Species Signaling Promotes Platelet Activation

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

A Combination of CD302 gene Expression and 3-Months BCR-ABL1 Level Predicts Inferior Achievement of Deep Molecular Response in CP-CML Patients Treated with Imatinib

Prospective Evaluation of ABL Kinase Domain Mutational Analysis By Next-Generation-Sequencing in Newly Diagnosed CP CML Patients Undergoing First-Line Treatment with Nilotinib Alone or Nilotinib + Pegylated Interferon-α2a in a Prospective Phase III Trial

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

HDAC8 Promotes MLL-Rearranged Acute Myeloid Leukemia By Inhibiting p53 Acetylation

Characterization of Recombinant β2GPI Using Hydrogen-Deuterium Exchange and X-Ray Crystallography

In Vitro Functionality of hiPSC Derived PLT+: The Utility of Microfluidic Assays in Determining Potency

Prothrombotic State, Platelet Activation and Netosis in Systemic Lupus Erythematosus

Fibrinogen-Mediated Platelet Microaggregate Formation in Stored Whole Blood

Platelet and Immune Characteristics of Patients with Immune Thrombocytopaenia Non Responders to Therapeutic Treatments

Dominant Role of αIIbβ3 in Platelet Interactions with Polymerizing Cross-Linked Fibrin

RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia

Cell Type-Specific Effects of Crizotinib in Human Acute Myeloid Leukemia with TP53 Alterations

Combination of Dasatinib and Pediatric-Inspired Regimens in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Single-Center Prospective Study

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

The Relationship between Molecular Response of BCR-ABL1 Transcripts within 6 Months and Deep Molecular Response at 18 Months to Dasatinib Treatment for Newly Diagnosed Patients with CML-CP

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only